one use of zinc is in zinc oxide to keep pecan trees healthy but it is needed as a trace mineral in many applications need to do your homework.
teddy, you are very accurate on your reporting the only thing I feel could be off is that you feel it will be april when the banks meet and I feel they will work it out with the banks several months before determination and if things are still dire in oil then the cut could come in jan but most likely February.whnich is not a big difference in time for a 67 yr old. lol.
actually depo is down 15% from the preoffer price and down almost 45% from the offer of $33 that they didn't take because the board of DEPO said they wanted a fixed stock offer and got it of .95 shares, now the buyout cash value changes with the market and the market has not been kind lately to biopharma. AS it turns out the $33 offer was a good offer in todays scenario but I agree with the board on wanting a fixed stock offer but that helped hznp and bit DEPO but then they were going to be bitten anyhow. You have brought up a point that pro depo holders need to realize and that is that if the offer was not on the table this stock would be a lot lower.
geri, I thought they said they were going to do two more deals by yearend and depo wont happen until 3/2016 IMO at best. I don't see them cooling their heels that long. You definitely have changed your mind about the depo merger by your wording. It has been very frustrating but that is what hostile takeovers do.
I juist realized this is your first post under this moniker and as such should be your last. I thought of giving a cheeky response on my first response but decided not to and now I feel you are not really serious on your question and not the naïve twit that I originally thought. If you are then you really need to do your DD so that you don't expose yourself.
it is the same as it was wh.95en the price was high. IT IS ..95 shares of HZNP this was their last of 4 offers and has been the same no matter where the price of stock goes
that is funny especially for the kool aid drinkers that follow their BOD and ceo. for that many how many will commit suicide if this deal goes away and the stock drops another $5 more than likely that wont happen until the biopharma market has recovered from Hillarys remarks.
I have noticed that the poster that I called on so many misspeaks has not posted for days. maybe he has already changed his moniker or sold out
the price is trending back to conversion rate again the fact that it has traded over and below conversion rate only shows the manipulation that has been going on between these two stocks.
earnings per share and PE are very similar as is business plan.
the two current proxies are only to have called meetings and that is all you are giving permission for, if there are enough people and these issues only require 10% so they will pass then you will get additional proxies to remove poison pill and directors and then proxies to elect new directors assuming any lost their jobs. long and protracted
the price has been bouncing around from slightly below par to 80 cents above par. I would agree that if the price stays above par the deal will have to be changed or it wont happen and depo wont drop much if the deal fails but my feeling is that day trading is playing games and tat it drops back to par in the next few weeks.
thanks for the response, yes NOL are transferrable I can remember the hay day when a lot of companies where bought in the 1980s for those losses that were about to go bankrupt or through the court. I also thought large pharma used salesmen for different drugs and not all there drugs but was not sure and you where a salesman. I think the main reason they do this is they want a salesperson to be very knowledgable and able to answer questions and to be able to do so on a several pain drugs may be possible but when you have 5 or6 different types of drugs it is hard to keep on on so many platforms intelligently and not look bad. I think if the merger goes trough that the majority of the sales stall of depo will be kept and only the laggards released. Not only do they not have to train those on the appropriate drugs of depo but they already have the contacts and they have been increasing sales by almost 17% QOQ for market share which is impressive.
why is $33 hznp stock mopney not worth as much as $19 depo stock money. it is one of the most immature arguments I have seen repeated on this board.
With a click of a button you can convert stock to cash. I think there are only two reasons to use this argument, 1) not knowledgeable to talk about the deal or know anything about stocks
2) JUST TO #$%$ me off lol
no doubt what you say has merit but the tax savings are still there for 2016 because your tax loss can be used by Hznp to reduce its taxes still bringing more money to the bottom line and meanwhile the debt would have a less interest charge going to the bottom line also. It isn't like HZNP is sitting still on earning, it is growing as rapidly as you expect depo to grow and I agree with that growth. HZNP still has several drugs that sell through CVS and PBMs so that would continue, when depo raised nucynta's price 44% it didn't hurt their relationship. Nucynta is not an orphan drug so it is not likely that it can be raised further. You have been a salesman so I will have to defer to your opionion but I have a question does each salesman represent all drugs from a company or do they just handle a few?
if you are correct I would expect an early announcement of earnings to help their PR battle as I expect the same out of Hznp if good earnings beat.
I would agree with most of your comments, except I no longer except short term believe depo shares will fall much if the deal fails, they are down to a very low PE also. They do have a number of other drugs but none as promising as Nucynta, I have looked at prescription numbers and they are doing very well on increasing market share I do not believe we see a peak until 2020 at best.
the rest of your points I believe to be true plus hznp has FA actimune that is already approved for other uses that if approved will give a great increase in sales that depo shareholders would be taking part of. Both companies are doing well the real question is how much better will they do together and I think that is what is debated here. I feel as you do the synergies and tax savings will make them both do better together.
after reading zacks article on prescription growth I do believe your 35 cents is doable nice estimate. I normally do not like zacks but this was a well written article and gave a lot to back up their opinions. but $36 in 2017 is a long ways away but it is a double from here but only a little above the Hznp original offer. I will be glad I own both regardless of if merger goes through or not. nucynta is less addictive than my original thoughts also which makes me happy
that was a decent answer, I hope you are correct on earnings as they are about double the analysts, however I hold a lot of hznp and they have a number of drugs on the market and their earnings per share are higher per quarter even for what you hope depo's to be. but both are selling way to low compared to 2016 earnings estimates. I as one hznp shareholder have always hoped this deal wouldn't go through, I can understand why it has gone this way but TW should have just walked away as hostile takeovers are brutal.
yappy, I understand insurance esp medical can take 6 months and the accounts from stryker etc are more than likely on a quarterly basis so are on average 3 to 6 months behind. I think too much is being made of this to help short positions also but doubtful that it will go permanently away.